methotrexate – Page 5 – Communicable Diseases Research

Repurposing Methotrexate in Dampening SARS-CoV2-S1-Mediated IL6 Expression: Lessons Learnt from Lung Cancer

Article

Published on 2022-02-012022-10-04
Journal: Inflammation [Category] COVID19(2023년), SARS, 신약개발,

[키워드] ACE2 ACE2 expression acute respiratory syndrome affected angiotensin-converting enzyme 2 Atla Cell characteristic coronavirus Correlation analysis COVID-19 COVID-19 patient Critical dataset dysregulated effective therapy expression expressions FBP Folate-binding protein gp130 IL-6 IL6 increase in indicated Infection Inflammation Inflammatory response Inflammatory responses inverse correlation lesson Loss lung adenocarcinoma lung cancer lung tissue injury methotrexate Phosphorylation Protein qRT-PCR analysis repurposing rescued SARS-CoV-2 SARS-COV-2 infection similarity Spearman suggested transfected cells Treatment
[DOI] 10.1007/s10753-021-01536-6 PMC 바로가기 [Article Type] Article

Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases

류마티스 질환 환자에서 백신 접종에 대한 약화된 항-SARS-CoV-2 항체 반응

Article

Published on 2022-02-012022-09-12
Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] Abstract anti-SARS-CoV-2 antibody COVID-19 IMID methotrexate mRNA vaccine Patient psoriatic arthritis response to vaccination rheumatic disease Rheumatoid rheumatoid arthritis SARS-CoV-2 spondyloarthritis vaccination Viral vector vaccine
[DOI] 10.1016/j.jinf.2021.12.006 PMC 바로가기 [Article Type] Article

Effects of laser acupuncture tele-therapy for rheumatoid arthritis elderly patients

Randomized Controlled Trial

Published on 2022-02-012022-10-05
Journal: Lasers in medical science [Category] COVID19(2023년), SARS, 임상,

Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases

면역 매개 염증성 류마티스 질환 환자에서 SARS-CoV-2에 대한 mRNA 백신에 대한 면역 반응

Article

Published on 2022-01-012022-09-12
Journal: RMD Open [Category] SARS, 진단,

[키워드] abatacept age Autoimmune Autoimmune diseases B-cell CD4 CD8 Cellular immune response cellular response Cellular responses correlated COVID-19 cumulative deleterious effects demonstrated depleting dose drug Effect Efficacy elicited Gender glucocorticoid healthy controls humoral humoral responses identify immune response immune system immune system diseases Immune-mediated Immunosuppression immunotherapies infections Inflammatory introduced investigated leflunomide methotrexate mRNA mRNA vaccine mRNA vaccines naïve Patient patients with SARS-CoV-2 phase III trial preserved receiving reduce reduced responders response rheumatic disease rituximab SARS-CoV-2 SARS-CoV-2 vaccine selected Seroconversion seroconversion rate T-cell immune response T-lymphocyte subsets the vaccine Therapies therapy titre treated two-dose regimen vaccination Vaccine were excluded
[DOI] 10.1136/rmdopen-2021-001898 PMC 바로가기 [Article Type] Article

Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants

Medicine

Published on 2021-12-082022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] acute respiratory syndrome anti-SARS-CoV-2 IgG antibody autoimmune conditions autoimmune skin diseases Beijing benefit booster doses calculated Cancer case-control study condition CoronaVac coronavirus coronavirus disease COVID-19 COVID-19 infection greater humoral immune response IgG IgG antibody Immune-mediated immunogenicity Immunosuppressant Immunosuppressed Immunosuppression immunosuppressive therapies immunosuppressive therapy Inactivated COVID-19 vaccine Infection lack methotrexate neutralizing antibody participant Patient patients patients with HIV percentage positive Prednisolone receiving reduction respond poorly response SARS-CoV-2 seroconversion rate serum Sinovac Sinovac Life Sciences statistical significance study participant subject subset the vaccine therapy vaccination Vaccine vaccine dose were used
[DOI] 10.3389/fmed.2021.769845 PMC 바로가기 [Article Type] Medicine

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations

Supplement Articles

Published on 2021-12-052022-10-29
Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19,

Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic

Observational Study

Published on 2021-12-012022-10-05
Journal: International immunopharmacology [Category] SARS, 임상,

The therapeutic dilemma of immunosuppressive drugs for refractory cardiac sarcoidosis in COVID-19 infection

COVID-19 감염에서 내화성 심장 유육종증에 대한 면역 억제제의 치료 딜레마.

Case Reports

Published on 2021-12-012022-08-31
Journal: ESC heart failure [Category] MERS, SARS, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration arrhythmia Arrhythmias coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids COVID-19 COVID-19 infection Dexamethasone discharge effective High dose hospital Immunocompromised patient immunology immunosuppressive agent Immunosuppressive agents immunosuppressive drug interruption intravenous Intravenous administration life-threatening maintenance dose methotrexate outbreak pandemic Patient patients with COVID-19 Prednisolone receiving refractory Refractory cardiac sarcoidosis regimen respiratory resulting sarcoidosis SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutic therapy treated Treatment ventricular woman
[DOI] 10.1002/ehf2.13676 PMC 바로가기 [Article Type] Case Reports

Juvenile Idiopathic Arthritis and COVID-19 Pandemic: Good Compliance With Treatment, Reluctance to Return to School

Medicine

Published on 2021-11-122022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

Articles

Published on 2021-11-092022-10-29
Journal: The Lancet Rheumatology [Category] COVID-19,

[키워드] 95% CI Administered All participant Alpha Antibody Response B.1.1.7 B.1.617.2 BNT162b2 Cell cellular cellular immunity cellular response Cohort cohort study college Control COVID-19 vaccine defined Delta variants demonstrated detectable eight England evaluated extended interval finding foundation functional funding General population group healthy control healthy controls Humoral immunity IL-17 IL-2 IL-21 IL-23 immune response Immune-mediated inflammatory disease immunogenicity Immunosuppressant Immunosuppression individual inhibitor inhibitors interferon-γ IQR King London longitudinal cohort study magnitude male median median age methotrexate monotherapy Necrosis neutralising antibody Neutralising antibody responses neutralising antibody titre NHS NIHR no difference of BNT162b2 participant Patient Pfizer-BioNTech Primary outcome producing proportion psoriasis receiving recruited regimen robust SARS-CoV-2 variants second dose second vaccination single dose spike glycoprotein Spike-specific antibody spike-specific IgG spike-specific T-cell response study population T-cell Response the SARS-CoV-2 Thoma titre TNF Trust vaccination vaccine dose vaccine doses Volunteer white wild-type
[DOI] 10.1016/S2665-9913(21)00333-7 PMC 바로가기 [Article Type] Articles